Parkinson's Disease and Visual Function: Retinal Pathology and Functional Readouts in Preclinical Models

Detecting the earliest functional consequence of retinal alpha-synuclein pathology is a methodological challenge because the canonical PD readouts (motor scoring, dopaminergic neuron counts) develop late and require either terminal histology or weeks of repeated motor testing. In the retina, alpha-synuclein is detectable immunohistochemically before overt photoreceptor loss, but a parallel non-invasive functional readout has been missing. Because rods are the dominant photoreceptor in mouse retina and are highly metabolically demanding, they are plausibly the first cell type to register molecular stress -- yet conventional photopic visual testing pools rod and cone contributions and may miss an early, rod-selective deficit.

A practical scotopic-vision protocol that can be repeated weekly or fortnightly in the same animal -- and that controls stimulus luminance precisely enough to isolate rod-driven responses from mesopic and photopic responses -- is therefore the missing methodological link between retinal molecular pathology and longitudinal functional read-out in PD models.

Microglial activation is a feature of both Parkinson's disease and many models of retinal degeneration, but disentangling whether neuroinflammation is a downstream consequence of degenerating photoreceptors or an independent driver of further damage remains a long-standing problem. In the retina, microglial activation is observable by IBA1 immunohistochemistry but only as terminal endpoints, so the temporal relationship between molecular pathology, microglial response, and functional vision loss is hard to resolve in a single cohort.

For interventions targeted at neuroinflammation -- ranging from CSF1R inhibitors to anti-inflammatory diets -- a non-invasive, repeatable functional readout is needed to separate the inflammatory contribution from the underlying photoreceptor pathology. A method that can resolve a treatment-induced functional inflection point against a progressive baseline is more informative than a single terminal histological comparison.

The most informative preclinical PD studies would test interventions across multiple endpoints simultaneously: dopaminergic neuron survival, motor performance, cognitive measures, and -- ideally -- a non-invasive longitudinal biomarker that correlates with disease progression. In humans, retinal nerve fibre layer thinning and contrast sensitivity decline both correlate with PD progression and have shown sensitivity to dopaminergic therapy. The corresponding preclinical question is whether rodent retinal functional readouts behave similarly: do they progress in parallel with classical PD markers, do they respond to disease-modifying interventions in the same direction as motor outcomes, and at what stage do they become sensitive enough to distinguish treated from untreated cohorts?

Answering this question requires longitudinal study designs in which the same animals are tested repeatedly across the disease course -- a setup for which non-invasive optomotor testing is uniquely suited and which terminal histology cannot deliver.